Pacira BioSciences, Inc.

Valuation Analysis

About the Company

Pacira BioSciences, Inc. en bref

Pacira BioSciences, Inc. (PCRX) is currently trading at 19,47 € with a market capitalization of 766 M €. The trailing P/E ratio stands at 171.77x, with a forward P/E of 6.12x. The 52-week range spans from 16,39 € to 24,10 €; the current price is 19.2% below the yearly high. Year-over-year revenue growth stands at +5.0%. The net profit margin stands at 0.7%.

💰 Dividende

Pacira BioSciences, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

6 analystes évaluent Pacira BioSciences, Inc. (PCRX) au consensus : Acheter. L'objectif de cours moyen est de 25,87 €, soit un potentiel de +32.86% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 20,05 € à 33,13 €.

Pacira BioSciences, Inc. : la thèse d'investissement en détail

Pacira BioSciences, Inc. (PCRX) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 79.33%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 32.86% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

With a net margin of just 0.7%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Short interest sits at 24.24% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

At a PEG of 11.21, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 9.13x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 6.12x is meaningfully below the trailing 171.77x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 32.86% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (24.24%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Pacira BioSciences, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.